كتاب
Pharmacological Approach to Type 1 Diabetes in Adults
- Executive Summary
The prevalence of type 1 diabetes is globally increasing around 2 million with high incidence of acute and chronic complications and the majority of the patients remain uncontrolled despite the presence of many insulin regimens and many new insulin analogues as well as the great improvement of insulin delivery systems.
This guideline provides recommendations for the pharmacological approach to type1 diabetes in adults.
➡️Recommendations
▪️ Treat most adults with type 1 diabetes with multiple daily doses of prandial and basal insulin Strong recommendation ▪️ For most adults with type 1 diabetes, insulin analogs are preferred over injectable human insulins to minimize hypoglycemia risk. Conditional recommendation ▪️ Automated Insulin delivery systems (insulin pens) and insulin analogues could be considered for all adults with type 1 diabetes. Conditional recommendation ▪️ To improve glycemic outcomes and quality of life and minimize hypoglycemia risk, most adults with type 1 diabetes should receive education on how to match mealtime insulin doses to carbohydrate intake and, additionally, to fat and protein intake. They should also be taught how to modify the insulin dose (correction dose) based on concurrent glycemia, glycemic trends (if available), sick-day management, and anticipated physical activity. Strong recommendation ▪️ Insulin treatment plan and insulin-taking behavior should be reevaluated at regular intervals (e.g., every 3–6 months) and adjusted to incorporate specific factors that impact choice of treatment and ensure achievement of individualized glycemic goals. Good practice statement |
